Adaptimmune And Astellas Team Up For Off-The-Shelf T-Cell Therapies
Could Be Worth $900m
News of the deal emerged as the UK firm's shares skyrocketed after its SPEAR T-cell platform delivered responses in four solid tumor types.
You may also be interested in...
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
Tecentriq is the only checkpoint inhibitor to get approval for first-line TNBC but failure in a second study for that indication will encourage rival Merck & Co with Keytruda nearing approval.